Zhiyin Oriental

Beijing Zhiyin Oriental Translational Medicine Research Center Co., Ltd. is a research institution in translational medicine. The center has a professional team composed of several biomedical professors and doctors with overseas and Chinese Academy of Sciences backgrounds. Its technical officer is Dr. Y.F. Zhou, from the MD Anderson Cancer Center in the United States, an anti-tumor research institution.\r\nZhiyin Oriental Translational Medicine Research Center is a leader in the field of precision medicine, possessing a big data analysis platform for precision medicine in the industry and constructing a complete solution in the field. The company's current business scope covers four major areas: genetic diseases, tumors, pharmacogenomics, and health management. By building a precision medicine database and big data algorithms, Zhiyin Oriental has achieved clinical-grade gene data analysis and become a leader in precision medicine and big data medicine.\r\nBeijing CATI Medical Technology Co., Ltd. is a leader in the integration of blood tumor diagnosis and treatment in China: it uses high-throughput sequencing to analyze tumor mutations and fusion genes. It has cutting-edge personalized multi-target cancer immunotherapy technology (similar technology has been successfully applied in melanoma in the United States and Germany, published in Nature in July 2017). The scientific advisors of its CAR-T business platform come from the University of Pennsylvania in the United States in the field of immune cell therapy. For solid tumor integration: the company has launched liquid biopsy projects in the industry; it combines liquid biopsy with broad-spectrum DC vaccines targeting Neoantigen and other precision immune cell therapy technologies.